Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway

Core Insights - Arrowhead Pharmaceuticals, Inc. (ARWR) achieved a significant milestone with the approval of their lead drug candidate REDEMPLO™ (formerly known as Plozasiran) on November 18th [1] Company Summary - REDEMPLO™ represents a transformational advancement for Arrowhead Pharmaceuticals, marking a pivotal moment in the company's development pipeline [1]